Eli Lilly and Company (NYSE:LLY) Shares Purchased by Biltmore Family Office LLC

Biltmore Family Office LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.8% during the second quarter, HoldingsChannel.com reports. The firm owned 3,005 shares of the company’s stock after purchasing an additional 81 shares during the period. Biltmore Family Office LLC’s holdings in Eli Lilly and Company were worth $2,721,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of LLY. AMJ Financial Wealth Management purchased a new position in Eli Lilly and Company during the fourth quarter worth approximately $201,000. Aveo Capital Partners LLC boosted its position in Eli Lilly and Company by 8.2% during the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after purchasing an additional 153 shares in the last quarter. Gryphon Financial Partners LLC boosted its position in Eli Lilly and Company by 19.4% during the fourth quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after purchasing an additional 377 shares in the last quarter. Foundations Investment Advisors LLC boosted its position in Eli Lilly and Company by 100.9% during the fourth quarter. Foundations Investment Advisors LLC now owns 20,168 shares of the company’s stock worth $11,756,000 after purchasing an additional 10,128 shares in the last quarter. Finally, Wealth Advisors of Iowa LLC boosted its position in Eli Lilly and Company by 2.0% during the fourth quarter. Wealth Advisors of Iowa LLC now owns 898 shares of the company’s stock worth $524,000 after purchasing an additional 18 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Barclays raised their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Berenberg Bank raised their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. BMO Capital Markets raised their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Jefferies Financial Group raised their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $961.76.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 661,900 shares of company stock valued at $604,721,602 over the last 90 days. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $901.28 on Wednesday. The firm has a market cap of $856.60 billion, a PE ratio of 132.74, a price-to-earnings-growth ratio of 2.73 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $972.53. The business’s fifty day simple moving average is $895.74 and its 200-day simple moving average is $830.47.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Equities analysts forecast that Eli Lilly and Company will post 16.51 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were given a $1.30 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.58%. Eli Lilly and Company’s payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.